Power and Sample Size Calculations for SNP Association Studies With Censored Time-to-Event Outcomes

Genetic Epidemiology

Volumn 36, Issue 6, 2012, Pages 538-548

  Owzar, Kouros ^a   Li, Zhiguo ^a   Cox, Nancy ^b   Jung, Sin Ho ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Censoring pharmacogenomics; Cox score test; Genetic risk; SNP association study

Indexed keywords

ALLELE; ARTICLE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC MODEL; GENETIC RISK; OUTCOME ASSESSMENT; POWER ANALYSIS; RISK ASSESSMENT; SAMPLE SIZE; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MODELS, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RANDOM ALLOCATION; RESEARCH DESIGN; SAMPLE SIZE; SOFTWARE; SURVIVAL RATE;

EID: 84865078027     PISSN: 07410395     EISSN: 10982272     Source Type: Journal    
DOI: 10.1002/gepi.21645     Document Type: Article

References (29)

1. Dahl DB. 2012. xtable: Export tables to LaTeX or HTML, R package version 1.7-0.
2. De La Vega F, Gordon D, Su X, Scafe C, Isaac H, Gilbert D, Spier E. 2005. Power and sample size calculations for genetic case/control studies using gene-centric SNP maps: application to human chromosomes 6, 21, and 22 in three populations. Hum Hered 60(1): 43-60.
3. Eddelbuettel D, Francois R. 2011. Rcpp: seamless R and C++ integration. J Stat Softw 40(8): 1-18.
4. Edwards B, Haynes C, Levenstien M, Finch S, Gordon D. 2005. Power and sample size calculations in the presence of phenotype errors for case/control genetic association studies.. BMC Genet 6(1): 18.
5. Fleming T, Harrington D. 1991. Counting Processes and Survival Analysis. New York: Wiley.
6. Galassi M, Davies J, Theiler J, Gough B, Jungman P, Alken P, Booth M, Rossi F. 2009. GNU Scientific Library Reference Manual (3rd ed.) Bristol, UK: Network Theory Ltd.
7. Gordon D, Finch SJ, Nothnagel M, Ott J. 2002. Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms. Hum Hered. 54(1):22-33.
8. Hao K, Xu X, Laird N, Wang X, Xu X. 2004. Power estimation of multiple SNP association test of case-control study and application. Genet Epidemiol 26(1): 22-30.
9. Hsieh F, Lavori P. 2000. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 21(6): 552-560.
10. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. 2012. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 18(2):577-584.
11. Jung S. 2005. Sample size for FDR-control in microarray data analysis. Bioinformatics 21(14): 3097--3104.
12. Jung S, Hui S. 2002. Sample size calculation for rank tests comparing k survival distributions. Lifetime Data Analysis 8(4): 361-373.
13. Kelly W, Halabi S, Carducci M, George D, Mahoney J, Stadler W, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small, EJ. 2012. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30(13):1534-1540.
14. Kindler H, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy M, O'Reilly E, Wozniak T, Picus J, Bhargava P, Mayer R, Schilsky R, Goldberg R. 2010. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28(22): 3617--3622.
15. Klein R. 2007. Power analysis for genome-wide association studies. BMC Genet 8(1): 58.
16. Lange C, DeMeo D, Silverman E, Weiss S, Laird N. 2004. PBAT: tools for family-based association studies. Am J Hum Genet. 74(2): 367--369.
17. Menashe I, Rosenberg P, Chen B. 2008. PGA: power calculator for case-control genetic association analyses.. BMC Genet 9(1): 36.
18. Neuwirth E. 2007. RColorBrewer: ColorBrewer palettes, R package version 1.0-2.
19. R Development Core Team. 2011. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
20. Revolution Analytics. 2012. foreach: Foreach looping construct for R, R package version 1.3.5.
21. Sarkar D. 2008. Lattice: Multivariate Data Visualization with R. New York: Springer.
22. Sarkar D, Andrews F. 2011. latticeExtra: Extra graphical utilities based on lattice, R package version 0.6-16.
23. Schoenfeld D. 1983. Sample-size formula for the proportional-hazards regression model. Biometrics 39(2): 499-503.
24. Sharpsteen C, Bracken C. 2011. tikzDevice: A device for R graphics output in PGF/TikZ format, R package version 0.6.1.
25. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan RO, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. 2012. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to 4 cycles as adjuvant chemotherapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101. J Clin Oncology. In press.
26. Skol A, Scott L, Abecasis G, Boehnke M. 2006. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38(2): 209-213.
27. Spencer C, Su Z, Donnelly P, Marchini J. 2009. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 5(5): e1000477.
28. Therneau T. 2011. survival: Survival analysis, including penalised likelihood, R package version 2.36-9.
29. van der Vaart A, Wellner J. 1996. Weak Convergence and Empirical Processes. New York: Springer-Verlag.